Investopedia: Will Immunotherapy Disrupt The Oncology Market?

Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to u...

Seeking Alpha: Receptos Could Meet With A More Positive Reception

Investors do well to be very skeptical of the biotech companies that go public in the late stages of a multi-year bull market. In many case...

Seeking Alpha: Can Tiny Synergetics See A Big Surge?

Having made some solid capital gains from various ophthalmology and niche med-tech companies in the past, I looked into Synergetics ( SURG ...

Investopedia: After A Sharp Pullback, Is Allergan Pretty Enough?

With its very strong (and lucrative) positions in markets like aesthetics (including the well-known Botox), eye care, device-based plastic...

MassDevice: Is Valeant About To Make A Bold Bid For Bausch & Lomb?

Never let it be said that Valeant (NYSE: VRX) management is shy about doing deals. With a roster of past deals including Biovail, Cephalon,...

Investopedia: After A Good Run, Novartis Looks Fairly Valued

Like so many other pharmaceutical stocks, Novartis (NYSE: NVS ) has done pretty well for its shareholders over the past year and solidly be...

Investopedia: AstraZeneca Pays Up To Patch Up Another Key Area

Pascal Soriot is still hard at work in patching up AstraZeneca 's (NYSE: AZN ) battered pipeline and five-year profit prospects. Followi...

Investopedia: Teva Still Too Cheap, But Still Too Uncertain

The story on the generics giant Teva Pharmaceutical (Nasdaq: TEVA ) really hasn't changed all that much over the past year. For invest...